Beacon Therapeutics reports positive 12-month data from Phase 2 trial of AGTC-501
In males with XLRP, the 12-month data demonstrated a response rate of 63% in study eyes treated with…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
09 Feb 24
In males with XLRP, the 12-month data demonstrated a response rate of 63% in study eyes treated with…
09 Feb 24
Following the positive results of the TAK-861-2001 study, the Japanese pharma major intends to quickly launch global Phase…
09 Feb 24
Using novel digital twins of clinical trial participants, Unlearn is accelerating clinical research to help bring new treatments…
07 Feb 24
The Phase 2, multi-centre, randomised, double-masked, parallel group study will assess the efficacy and safety of KHK4951 in…
02 Feb 24
According to the long-term data, around 60% of people getting Vabysmo in BALATON and up to 48% of…
31 Jan 24
In both randomised controlled trials for abdominoplasty and bunionectomy, treatment with VX-548 resulted in a statistically significant improvement…
31 Jan 24
QIAGEN Digital Insights (QDI), the bioinformatics business of QIAGEN, today announced their enhanced QIAGEN CLC Genomics Workbench Premium…
30 Jan 24
In the trial, SRP-5051, at the higher, target dose, resulted in mean dystrophin expression of 5.17%, and mean…
24 Jan 24
Obese participants, who were administered with up to 30mg oral ecnoglutide once-daily for six weeks, achieved a mean…
23 Jan 24
The late-stage trial is evaluating the Trop-2-directed antibody-drug conjugate in 603 previously treated metastatic NSCLC in comparison to…